{
    "root": "26d97068-113c-452d-a698-e0dd2c38f105",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Budesonide",
    "value": "20250522",
    "ingredients": [
        {
            "name": "BUDESONIDE",
            "code": "Q3OKS62Q6X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3207"
        },
        {
            "name": "CETYL ALCOHOL",
            "code": "936JST6JCN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "ETHYLCELLULOSES",
            "code": "7Z8S9VYZ4B",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11228"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "METHYL ALCOHOL",
            "code": "Y4S76JWI15",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29309"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        }
    ],
    "indications": {
        "text": "budesonide delayed-release capsules corticosteroid indicated : treatment mild moderate active crohn \u2019 disease involving ileum and/or ascending colon , patients 8 years older . ( 1.1 ) maintenance remission mild moderate crohn \u2019 disease involving ileum and/or ascending colon 3 months adults . ( 1.2 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "instructions ( 2.1 ) : take daily morning . swallow whole . chew crush . patients unable swallow intact capsule , open capsules empty granules onto one tablespoonful applesauce . mix consume entire contents within 30 minutes . chew crush . follow 8 ounces water . avoid consumption grapefruit juice duration therapy . recommended : mild moderate active crohn \u2019 disease ( 2.2 ) : adults : 9 mg daily 8 weeks ; repeat 8 week treatment courses recurring episodes active disease . pediatrics 8 17 years weigh 25 kg : 9 mg daily 8 weeks , followed 6 mg daily morning 2 weeks . maintenance remission mild moderate crohn \u2019 disease ( 2.3 ) : adults : 6 mg daily 3 months ; taper complete cessation 3 months . continued treatment 3 months shown provide substantial benefit . switching oral prednisolone , begin tapering prednisolone concomitantly initiating budesonide delayed-release capsules . hepatic impairment : consider reducing 3 mg daily adult patients moderate hepatic impairment ( child-pugh class b ) . ( 2.4 , 5.1 , 8.6 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "budesonide delayed-release capsules , 3 mg , supplied hard gelatin capsules opaque light gray body imprinted \u201c 778 \u201d opaque maroon cap imprinted \u201c amneal \u201d black ink . available follows : bottles 100 : ndc 53746-778-10 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . keep container tightly closed .",
    "adverseReactions": "budesonide delayed-release capsules contraindicated patients hypersensitivity budesonide ingredients budesonide delayed-release capsules . serious hypersensitivity , including anaphylaxis occurred [ ( 6.2 ) ] .",
    "indications_original": "Budesonide delayed-release capsules are a corticosteroid indicated for: Treatment of mild to moderate active Crohn\u2019s disease involving the ileum and/or the ascending colon, in patients 8 years and older. ( 1.1 ) Maintenance of clinical remission of mild to moderate Crohn\u2019s disease involving the ileum and/or the ascending colon for up to 3 months in adults. ( 1.2 )",
    "contraindications_original": "Administration Instructions ( 2.1 ): Take once daily in the morning. Swallow whole. Do not chew or crush. For patients unable to swallow an intact capsule, open the capsules and empty the granules onto one tablespoonful of applesauce. Mix and consume the entire contents within 30 minutes. Do not chew or crush. Follow with 8 ounces of water. Avoid consumption of grapefruit juice for the duration of therapy. Recommended Dosage: Mild to moderate active Crohn\u2019s disease ( 2.2 ): Adults: 9 mg once daily for up to 8 weeks; repeat 8 week treatment courses for recurring episodes of active disease. Pediatrics 8 to 17 years who weigh more than 25 kg: 9 mg once daily for up to 8 weeks, followed by 6 mg once daily in the morning for 2 weeks. Maintenance of clinical remission of mild to moderate Crohn\u2019s disease ( 2.3 ): Adults: 6 mg once daily for up to 3 months; taper to complete cessation after 3 months. Continued treatment for more than 3 months has not been shown to provide substantial clinical benefit. When switching from oral prednisolone, begin tapering prednisolone concomitantly with initiating budesonide delayed-release capsules. Hepatic Impairment: Consider reducing the dosage to 3 mg once daily in adult patients with moderate hepatic impairment (Child-Pugh Class B). ( 2.4 , 5.1 , 8.6 )",
    "warningsAndPrecautions_original": "Budesonide delayed-release capsules, 3 mg, are supplied as hard gelatin capsules with an opaque light gray body imprinted \u201c778\u201d and an opaque maroon cap imprinted \u201cAMNEAL\u201d with black ink.\n                  They are available as follows: \n                  Bottles of 100:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 53746-778-10\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]. \n                  Keep container tightly closed.",
    "adverseReactions_original": "Budesonide delayed-release capsules are contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of budesonide delayed-release capsules. Serious hypersensitivity reactions, including anaphylaxis have occurred\u00a0[see Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "Budesonide",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3207"
        }
    ]
}